163 related articles for article (PubMed ID: 38129572)
1. Hyperactive Natural Killer cells in Rag2 knockout mice inhibit the development of acute myeloid leukemia.
Sugimoto E; Li J; Hayashi Y; Iida K; Asada S; Fukushima T; Tamura M; Shikata S; Zhang W; Yamamoto K; Kawabata KC; Kawase T; Saito T; Yoshida T; Yamazaki S; Kaito Y; Imai Y; Denda T; Ota Y; Fukuyama T; Tanaka Y; Enomoto Y; Kitamura T; Goyama S
Commun Biol; 2023 Dec; 6(1):1294. PubMed ID: 38129572
[TBL] [Abstract][Full Text] [Related]
2. NK cells play a significant role in immunosurveillance at the early stage of MLL-AF9 acute myeloid leukemia via CD226/CD155 interactions.
Wang Y; Chen C; Dong F; Ma S; Xu J; Gong Y; Cheng H; Zhou Y; Cheng T; Hao S
Sci China Life Sci; 2015 Dec; 58(12):1288-98. PubMed ID: 26588911
[TBL] [Abstract][Full Text] [Related]
3. Perforin-dependent direct cytotoxicity in natural killer cells induces considerable knockdown of spontaneous lung metastases and computer modelling-proven tumor cell dormancy in a HT29 human colon cancer xenograft mouse model.
Brodbeck T; Nehmann N; Bethge A; Wedemann G; Schumacher U
Mol Cancer; 2014 Nov; 13():244. PubMed ID: 25373310
[TBL] [Abstract][Full Text] [Related]
4. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
5. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.
Romee R; Rosario M; Berrien-Elliott MM; Wagner JA; Jewell BA; Schappe T; Leong JW; Abdel-Latif S; Schneider SE; Willey S; Neal CC; Yu L; Oh ST; Lee YS; Mulder A; Claas F; Cooper MA; Fehniger TA
Sci Transl Med; 2016 Sep; 8(357):357ra123. PubMed ID: 27655849
[TBL] [Abstract][Full Text] [Related]
6. In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity.
Nakata J; Nakano K; Okumura A; Mizutani Y; Kinoshita H; Iwai M; Hasegawa K; Morimoto S; Fujiki F; Tatsumi N; Nakajima H; Nakae Y; Nishida S; Tsuboi A; Oji Y; Oka Y; Sugiyama H; Kumanogoh A; Hosen N
Leukemia; 2014 Jun; 28(6):1316-25. PubMed ID: 24336127
[TBL] [Abstract][Full Text] [Related]
7. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
8. Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia.
Bou-Tayeh B; Laletin V; Salem N; Just-Landi S; Fares J; Leblanc R; Balzano M; Kerdiles YM; Bidaut G; Hérault O; Olive D; Aurrand-Lions M; Walzer T; Nunès JA; Fauriat C
Front Immunol; 2021; 12():730970. PubMed ID: 34975835
[TBL] [Abstract][Full Text] [Related]
9. Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia.
Hayashi Y; Goyama S; Liu X; Tamura M; Asada S; Tanaka Y; Fukuyama T; Wunderlich M; O'Brien E; Mizukawa B; Yamazaki S; Matsumoto A; Yamasaki S; Shibata T; Matsuda K; Sashida G; Takizawa H; Kitamura T
Nat Commun; 2019 Oct; 10(1):4869. PubMed ID: 31653912
[TBL] [Abstract][Full Text] [Related]
10. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-29b mediates altered innate immune development in acute leukemia.
Mundy-Bosse BL; Scoville SD; Chen L; McConnell K; Mao HC; Ahmed EH; Zorko N; Harvey S; Cole J; Zhang X; Costinean S; Croce CM; Larkin K; Byrd JC; Vasu S; Blum W; Yu J; Freud AG; Caligiuri MA
J Clin Invest; 2016 Dec; 126(12):4404-4416. PubMed ID: 27775550
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid mediated differential activation of NK cells in different organs of WT and Rag2
Kaur K; Kanayama K; Wu QQ; Gumrukcu S; Nishimura I; Jewett A
Cell Immunol; 2022 May; 375():104526. PubMed ID: 35500335
[TBL] [Abstract][Full Text] [Related]
13. Siglec-7 is an indicator of natural killer cell function in acute myeloid leukemia.
Yang L; Feng Y; Wang S; Jiang S; Tao L; Li J; Wang X
Int Immunopharmacol; 2021 Oct; 99():107965. PubMed ID: 34273636
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.
Aggarwal N; Swerdlow SH; TenEyck SP; Boyiadzis M; Felgar RE
Cytometry B Clin Cytom; 2016 Jul; 90(4):349-57. PubMed ID: 26648320
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of NK cells from leukemic microenvironment in MLL-AF9 induced acute myeloid leukemia.
Yang F; Wang R; Feng W; Chen C; Yang X; Wang L; Hu Y; Ren Q; Zheng G
Mol Immunol; 2018 Jan; 93():68-78. PubMed ID: 29154208
[TBL] [Abstract][Full Text] [Related]
16. Decitabine enhances targeting of AML cells by CD34
Cany J; Roeven MWH; Hoogstad-van Evert JS; Hobo W; Maas F; Franco Fernandez R; Blijlevens NMA; van der Velden WJ; Huls G; Jansen JH; Schaap NPM; Dolstra H
Blood; 2018 Jan; 131(2):202-214. PubMed ID: 29138222
[TBL] [Abstract][Full Text] [Related]
17. NK cell defects: implication in acute myeloid leukemia.
D'Silva SZ; Singh M; Pinto AS
Front Immunol; 2023; 14():1112059. PubMed ID: 37228595
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
Front Immunol; 2018; 9():977. PubMed ID: 29780393
[TBL] [Abstract][Full Text] [Related]
19. Adaptive single-KIR
Haroun-Izquierdo A; Vincenti M; Netskar H; van Ooijen H; Zhang B; Bendzick L; Kanaya M; Momayyezi P; Li S; Wiiger MT; Hoel HJ; Krokeide SZ; Kremer V; Tjonnfjord G; Berggren S; Wikström K; Blomberg P; Alici E; Felices M; Önfelt B; Höglund P; Valamehr B; Ljunggren HG; Björklund A; Hammer Q; Kveberg L; Cichocki F; Miller JS; Malmberg KJ; Sohlberg E
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319065
[TBL] [Abstract][Full Text] [Related]
20. Development of functional human NK cells in an immunodeficient mouse model with the ability to provide protection against tumor challenge.
Kwant-Mitchell A; Pek EA; Rosenthal KL; Ashkar AA
PLoS One; 2009 Dec; 4(12):e8379. PubMed ID: 20027308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
